Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy.
A double-blind randomized cross-over trial of dexamethasone and prochlorperazine as adjunctive anti-emetics with cancer chemotherapy was undertaken. The drugs were compared for cisplatin, doxorubicin and several other chemotherapy regimens. A total of 44 eligible patients were analysed. Assessment was made by questionnaire answered by the patient 24 h after the chemotherapy. The parameters compared were period of time for nausea and vomiting, number of vomiting episodes, degree of somnolence and insomnia and overall preference. In all cases there was no significant difference for either drug in its ability to suppress emetic effects. Neither drug gave adequate protection against cisplatin-containing regimens. We conclude that dexamethasone alone is equivalent to the more standard dopamine antagonists.
Goldstein
D
D
Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.
Levi
J A
JA
Woods
R L
RL
Russell
J
J
Morgan
J
J
Kerestes
Z
Z
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D011346:Prochlorperazine / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D014839:Vomiting / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003907:Dexamethasone; D011346:Prochlorperazine